コンテンツへスキップ
Merck
すべての画像(2)

主要文書

安全性情報

SAB4502541

Sigma-Aldrich

Anti-CD45 antibody produced in rabbit

affinity isolated antibody

別名:

L-CA, LY-5, Leukocyte common antigen precursor, Leukocyte common antigen variant 4 precursor, Lymphocyte common antigen Ly-5

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352203
NACRES:
NA.41

由来生物

rabbit

品質水準

結合体

unconjugated

抗体製品の状態

affinity isolated antibody

抗体製品タイプ

primary antibodies

クローン

polyclonal

フォーム

buffered aqueous solution

分子量

antigen 147 kDa

交差性

rat, mouse, human

濃度

~1 mg/mL

テクニック

ELISA: 1:1000
immunofluorescence: 1:100-1:500
immunohistochemistry: 1:50-1:100

NCBIアクセッション番号

UniProtアクセッション番号

輸送温度

wet ice

保管温度

−20°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

human ... PTPRC(5788)

詳細

Anti-CD45 antibody detects endogenous levels of total CD45 protein.
The CD45 (cluster of differentiation 45) gene is mapped to human chromosome 1q31.3-q32.1. It codes for a type I transmembrane protein and is expressed in nucleated hematopoietic cells along within its precursors. The protein consists of a varying extracellular domain and a highly conserved intracellular domain.

免疫原

The antiserum was produced against synthesized peptide derived from human CD45.

Immunogen Range: 981-1030

アプリケーション

Anti-CD45 antibody produced in rabbit has been used in:
  • immunohistochemistry staining
  • immunofluorescence staining
  • immunostaining

生物化学的/生理学的作用

The Cluster of differentiation 45 (CD45) facilitates the regulation of lymphocyte signaling and SRC family kinase Lck. This protein participates in the polymorphism in several mammalian species.
The protein encoded by CD45 (cluster of differentiation 45) is a prototypic receptor and exhibits phosphatase activity. CD45 is found to control T-cell mediated BCR-signaling.

特徴および利点

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

物理的形状

ウサギIgGのPBS溶液(Mg2+およびCa2+を含まず)、pH 7.4、150 mM NaCl、0.02% アジ化ナトリウム、50% グリセロール

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください

保管分類コード

12 - Non Combustible Liquids

WGK

nwg

引火点(°F)

Not applicable

引火点(℃)

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

SAB4502541-100UG:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

適切なバージョンが見つかりませんか。

特定のバージョンが必要な場合は、ロット番号またはバッチ番号で特定の証明書を検索できます。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

この製品を見ている人はこちらもチェック

Sathish Babu Vasamsetti et al.
Immunity, 49(1), 93-106 (2018-07-01)
There is a growing body of research on the neural control of immunity and inflammation. However, it is not known whether the nervous system can regulate the production of inflammatory myeloid cells from hematopoietic progenitor cells in disease conditions. Myeloid
T-helper signals restore B-cell receptor signaling in autoreactive anergic B cells by upregulating CD45 phosphatase activity.
Szodoray P
The Journal of Allergy and Clinical Immunology, 138(3), 839-851 (2016)
The soluble cytoplasmic tail of CD45 (ct-CD45) in human plasma contributes to keep T cells in a quiescent state.
Puck A
European Journal of Immunology, 47(1), 193-205 (2017)
Xiaoguang Wang et al.
Experimental and therapeutic medicine, 22(4), 1140-1140 (2021-09-11)
Pancreatic cancer (PC) is a highly malignant tumor type with a high early metastasis rate and no obvious symptoms. Gemcitabine is a first-line chemotherapeutic drug for PC. Since there is no distinct method to determine the efficacy of chemotherapy with
Ondřej Kodet et al.
International journal of molecular sciences, 22(13) (2021-07-21)
Therapy targeting immune checkpoints represents an integral part of the treatment for patients suffering from advanced melanoma. However, the mechanisms of resistance are responsible for a lower therapeutic outcome than expected. Concerning melanoma, insufficient stimulation of the immune system by

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)